Entera Bio Ltd ENTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
-
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
-
Correction: Entera to Participate in Upcoming Fall Investor Conferences
-
Entera to Participate in Upcoming Fall Investor Conferences
-
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
-
Entera Announces Second Quarter 2026 Financial Results and Business Updates
-
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
-
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Trading Information
- Previous Close Price
- $3.02
- Day Range
- $2.86–3.02
- 52-Week Range
- $0.91–4.20
- Bid/Ask
- $2.47 / $3.49
- Shares Outstanding
- 173.83M
- Market Cap
- $507.60M
- Volume/Avg
- 256,927 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 145.50
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 22
- Website
- https://www.enterabio.com
Valuation
|
Metric
|
ENTX
|
|---|---|
Price/Earnings (Normalized) | 145.50 |
Price/Book Value | 19.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENTX
Financial Strength
|
Metric
|
ENTX
|
|---|---|
Quick Ratio | 5.42 |
Current Ratio | 8.98 |
Interest Coverage | −5.47 |
Quick Ratio
ENTX
Profitability
|
Metric
|
ENTX
|
|---|---|
Return on Assets (Normalized) | −82.29% |
Return on Equity (Normalized) | −110.95% |
Return on Invested Capital (Normalized) | −87.77% |
Return on Assets
ENTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Y!T$$t | LOCK|?Gf% | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wQw%GYr | LOCK|$KL^ | $83B | |||
| Moderna Inc
MRNA
| LOCK|%<%$f?# | LOCK|$q | $80B | |||
| argenx SE ADR
ARGX
| LOCK|$tMNr%? | LOCK|#zx | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|D^k?SG | LOCK|&^ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?h%R!> | LOCK|F%z@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#J&cb%<q | LOCK|>kf# | $28B | |||
| Incyte Corp
INCY
| LOCK|$!P<%^t | LOCK|^n | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?!@^KG | LOCK|&w | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#CyDy#P | LOCK|bF? | $14B |
United States